Gotham Therapeutics has secured $ $40 million m in series A financing to develop its RNA-modifying protein therapies. Other participants included drugmaker Celgene and Alexandria Venture Investments. The investment was led by Versant Ventures , Celgene and S.R. One, with support from Forbion and RNA . The company is aiming to develop technologies related to the emerging field of epitranscriptomics, which differs from epigenetics by focusing on transcribing Alexandria Venture Investments into proteins rather than transcribing DNA into RNA . It is believed that development of the technology could have a significant impact on the treatment of numerous health problems, including cancers, autoimmune disorders and neurodegenerative diseases.
Gotham Therapeutics has secured $ $40 million m in series A financing to develop its RNA-modifying protein therapies. The investment was led by Versant Ventures , Celgene and S.R. One, with support from Forbion and RNA . The company is aiming to develop technologies related to the emerging field of epitranscriptomics, which differs from epigenetics by focusing on transcribing Alexandria Venture Investments into proteins rather than transcribing DNA into RNA . It is believed that development of the technology could have a significant impact on the treatment of numerous health problems, including cancers, autoimmune disorders and neurodegenerative diseases.